Analyst Oliver McCammon from LifeSci Capital maintained a Buy rating on Monte Rosa Therapeutics (GLUE – Research Report) and keeping the price target at $19.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oliver McCammon has given his Buy rating due to a combination of factors related to Monte Rosa Therapeutics’ promising developments in cancer treatment. The company is advancing its CDK2-directed molecular glue degrader, MRT-51443, which shows potential in treating HR-positive/HER2-negative breast cancer. This innovative approach targets CDK2, a mechanism that could overcome resistance in patients who have previously received CDK4/6 inhibitors.
Monte Rosa’s preclinical data, set to be presented at the AACR 2025, indicates that MRT-51443 can delay resistance to CDK4/6 inhibitors and achieve significant tumor regression when used in combination therapies. The potential for MRT-51443 to be used in various combination therapies, such as with endocrine therapy or other inhibitors, enhances its appeal as a versatile treatment option. This promising outlook, combined with the company’s strategic focus on cell cycle-directed degraders, supports McCammon’s optimistic assessment of Monte Rosa’s stock.